Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:BDTX NASDAQ:BMEA NASDAQ:BRNS NASDAQ:THAR On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeBDTXBlack Diamond Therapeutics$2.01$2.30$1.60▼$4.94$115.18M3.252.15 million shs1.57 million shsBMEABiomea Fusion$1.41$1.38$0.87▼$2.99$101.94M-0.311.01 million shs1.66 million shsBRNSBarinthus Biotherapeutics$0.62$0.67$0.51▼$2.92$25.33M-0.41164,967 shs86,194 shsTHARTharimmune$2.84-3.4%$3.11$0.95▼$9.08$107.15M1.431.48 million shs406,474 shsDon't Wait for the OpenAI IPOThe AI wave will soon hit public markets with Anthropic and OpenAI set to go public later this year. However, you don't have to wait to invest. This report shows seven AI stocks that you can buy today while the big model providers get ready to go public.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceBDTXBlack Diamond Therapeutics0.00%+17.54%-4.29%-15.90%-22.69%BMEABiomea Fusion0.00%+6.82%+8.46%-8.44%-14.55%BRNSBarinthus Biotherapeutics0.00%-11.41%-11.52%+8.79%-34.45%THARTharimmune-3.40%+5.77%+19.83%-12.88%+56.04%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeBDTXBlack Diamond Therapeutics$2.01$2.30$1.60▼$4.94$115.18M3.252.15 million shs1.57 million shsBMEABiomea Fusion$1.41$1.38$0.87▼$2.99$101.94M-0.311.01 million shs1.66 million shsBRNSBarinthus Biotherapeutics$0.62$0.67$0.51▼$2.92$25.33M-0.41164,967 shs86,194 shsTHARTharimmune$2.84-3.4%$3.11$0.95▼$9.08$107.15M1.431.48 million shs406,474 shsDon't Wait for the OpenAI IPOThe AI wave will soon hit public markets with Anthropic and OpenAI set to go public later this year. However, you don't have to wait to invest. This report shows seven AI stocks that you can buy today while the big model providers get ready to go public.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceBDTXBlack Diamond Therapeutics0.00%+17.54%-4.29%-15.90%-22.69%BMEABiomea Fusion0.00%+6.82%+8.46%-8.44%-14.55%BRNSBarinthus Biotherapeutics0.00%-11.41%-11.52%+8.79%-34.45%THARTharimmune-3.40%+5.77%+19.83%-12.88%+56.04%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceBDTXBlack Diamond Therapeutics 2.73Moderate Buy$9.83389.22% UpsideBMEABiomea Fusion 2.75Moderate Buy$8.50502.84% UpsideBRNSBarinthus Biotherapeutics 2.00Hold$4.00545.06% UpsideTHARTharimmune 1.00SellN/AN/ACurrent Analyst Ratings BreakdownLatest BRNS, THAR, BMEA, and BDTX Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails7/1/2026BMEABiomea Fusion Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeSell (D-) ➝ Sell (E+)6/16/2026BMEABiomea Fusion Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeSell (E+) ➝ Sell (D-)6/15/2026BRNSBarinthus Biotherapeutics Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeSell (E+) ➝ Sell (D-)5/28/2026BRNSBarinthus Biotherapeutics Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeSell (D-) ➝ Sell (E+)5/22/2026BDTXBlack Diamond Therapeutics Raymond James FinancialSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingOutperform5/22/2026BDTXBlack Diamond Therapeutics TD CowenSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy5/22/2026BDTXBlack Diamond Therapeutics HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy5/18/2026BDTXBlack Diamond Therapeutics Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeSell (D+) ➝ Sell (D)5/8/2026BRNSBarinthus Biotherapeutics Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeSell (E+) ➝ Sell (D-)5/5/2026BMEABiomea Fusion CitigroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy ➝ Outperform5/5/2026BMEABiomea Fusion Citizens JmpSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageMarket Outperform$9.00(Data available from 7/4/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookBDTXBlack Diamond Therapeutics$70M1.65$0.53 per share3.81$1.97 per share1.02BMEABiomea FusionN/AN/AN/AN/A$0.42 per shareN/ABRNSBarinthus Biotherapeutics$14.97M1.69N/AN/A$1.82 per share0.34THARTharimmuneN/AN/AN/AN/A$0.68 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateBDTXBlack Diamond Therapeutics$22.37M-$0.77N/AN/AN/AN/A-30.18%-23.91%8/6/2026 (Estimated)BMEABiomea Fusion-$61.80M-$0.68N/AN/AN/AN/A-265.37%-103.96%8/4/2026 (Estimated)BRNSBarinthus Biotherapeutics-$66.43M-$1.29N/AN/AN/AN/A-63.83%-48.77%8/6/2026 (Estimated)THARTharimmune-$12.20M-$3.99N/AN/AN/AN/A-588.45%-264.41%N/ALatest BRNS, THAR, BMEA, and BDTX EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/11/2026Q1 2026BMEABiomea Fusion-$0.24-$0.17+$0.07-$0.17N/AN/A5/7/2026Q1 2026BDTXBlack Diamond Therapeutics-$0.18-$0.16+$0.02-$0.16$25.00 millionN/A4/30/2026Q1 2026BRNSBarinthus Biotherapeutics-$0.28-$0.14+$0.14-$0.14N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthBDTXBlack Diamond TherapeuticsN/AN/AN/AN/AN/ABMEABiomea FusionN/AN/AN/AN/AN/ABRNSBarinthus BiotherapeuticsN/AN/AN/AN/AN/ATHARTharimmuneN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioBDTXBlack Diamond TherapeuticsN/A8.468.46BMEABiomea FusionN/A4.984.98BRNSBarinthus BiotherapeuticsN/A6.056.05THARTharimmuneN/A4.984.98Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipBDTXBlack Diamond Therapeutics95.47%BMEABiomea Fusion96.72%BRNSBarinthus Biotherapeutics25.20%THARTharimmune1.16%Insider OwnershipCompanyInsider OwnershipBDTXBlack Diamond Therapeutics9.29%BMEABiomea Fusion10.60%BRNSBarinthus Biotherapeutics8.50%THARTharimmune6.70%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableBDTXBlack Diamond Therapeutics9057.30 million51.98 millionOptionableBMEABiomea Fusion5072.30 million64.64 millionOptionableBRNSBarinthus Biotherapeutics10740.85 million37.38 millionN/ATHARTharimmune237.73 million35.20 millionNot OptionableBRNS, THAR, BMEA, and BDTX HeadlinesRecent News About These CompaniesTharimmune Inc.May 13, 2026 | wsj.comTharimmune Rebrands as Canton Strategic Holdings, Updates TickerFebruary 18, 2026 | tipranks.comIs Canton’s price set to explode amid Tharimmune’s rebrand?February 17, 2026 | invezz.comITharimmune, Inc. Announces Corporate Rebrand to Canton Strategic Holdings, Inc., Marking Milestone in Canton Network Digital Asset Treasury StrategyFebruary 17, 2026 | prnewswire.comCatherine Wood's Strategic Moves: A Closer Look at Tesla Inc's Portfolio ImpactFebruary 11, 2026 | finance.yahoo.comTharimmune, Inc. Appoints Mark Wendland Chairman of the Board and Names Angela Radkowski Chief Operating OfficerFebruary 6, 2026 | prnewswire.comTharimmune Elects Jill Sommers and William Wiley to Board of DirectorsFebruary 2, 2026 | prnewswire.comTharimmune Approved as Super Validator on Canton NetworkJanuary 27, 2026 | theglobeandmail.comTharimmune Announces Expanded Role as Super Validator on Canton NetworkJanuary 26, 2026 | prnewswire.comTharimmune, Inc. And The Canton Network: A Privacy Focused, Asymmetric Bet On TokenizationJanuary 23, 2026 | seekingalpha.comTharimmune, Inc. Announces Closing of $55 Million Underwritten Registered Direct OfferingJanuary 22, 2026 | prnewswire.comTharimmune, Inc. Announces Pricing of $55 Million Underwritten Registered OfferingJanuary 20, 2026 | prnewswire.comTharimmune, Inc. Statement on DTCC's Initiative to Tokenize U.S. Treasury Securities on the Canton NetworkDecember 18, 2025 | prnewswire.comTharimmune appoints Jacob Asbury as CFODecember 12, 2025 | msn.comTharimmune Appoints Jacob Asbury as New CFODecember 12, 2025 | tipranks.comTharimmune, Inc. Appoints Jacob Asbury as Chief Financial Officer to Advance Canton Coin Treasury StrategyDecember 12, 2025 | businesswire.comTharimmune files to sell 176.93M shares of common stock for holdersDecember 5, 2025 | msn.comCrypto Company Creates Bizarre DrugNovember 22, 2025 | msn.comTharimmune (NASDAQ:THAR) Shares Up 8.9% – What’s Next?November 22, 2025 | defenseworld.netDDigital Assets Firm Copper Serves as Custodian for Tharimmune, Inc. Canton Coin Treasury StrategyNovember 19, 2025 | crowdfundinsider.comCNew MarketBeat Followers Over TimeMedia Sentiment Over TimeBRNS, THAR, BMEA, and BDTX Company DescriptionsBlack Diamond Therapeutics NASDAQ:BDTX$2.01 0.00 (0.00%) Closing price 07/2/2026 04:00 PM EasternExtended Trading$2.00 -0.01 (-0.50%) As of 07/2/2026 07:43 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Black Diamond Therapeutics, Inc., a clinical-stage oncology medicine company, focuses on the discovery and development of MasterKey therapies for patients with genetically defined tumors. The company's lead product candidate is BDTX-1535, a brain-penetrant epidermal growth factor receptor MasterKey inhibitor, which is in phase 2 clinical trial for the treatment of epidermal growth factor receptor mutant non-small cell lung cancer, as well as phase 1 clinical trial to treat glioblastoma. It is also developing BDTX-4933, a brain-penetrant RAF MasterKey inhibitor targeting KRAS, NRAS, and BRAF alterations in solid tumors that is in phase 1 clinical trial. In addition, the company is developing BDTX-4876, a MasterKey inhibitor of oncogenic FGFR2/3 mutations with selectivity versus FGFR1/4, which is in preclinical stage. The company was formerly known as ASET Therapeutics, Inc. and changed its name to Black Diamond Therapeutics, Inc. in January 2018. Black Diamond Therapeutics, Inc. was incorporated in 2014 and is headquartered in Cambridge, Massachusetts.Biomea Fusion NASDAQ:BMEA$1.41 0.00 (0.00%) Closing price 07/2/2026 04:00 PM EasternExtended Trading$1.40 0.00 (-0.35%) As of 07/2/2026 07:37 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Biomea Fusion, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of covalent small molecule drugs to treat patients with genetically defined cancers and metabolic diseases. Its lead product candidate is BMF-219, a covalent inhibitor of menin for treating patients with liquid and solid tumors and type 2 diabetes. The company was incorporated in 2017 and is headquartered in Redwood City, California.Barinthus Biotherapeutics NASDAQ:BRNS$0.62 0.00 (0.00%) Closing price 07/2/2026 03:59 PM EasternExtended Trading$0.59 -0.03 (-4.53%) As of 07/2/2026 07:50 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Barinthus Biotherapeutics plc, a clinical-stage biopharmaceutical company, engages in development of novel T cell immunotherapeutic candidates designed to guide the immune system to overcome chronic infectious diseases, autoimmunity, and cancer. The company's development pipeline includes VTP-300, an immunotherapeutic candidate under phase 2 studies as a potential component of a functional cure for chronic hepatitis B virus (HBV) infection; VTP-200, a non-surgical product candidate under phase 2 studies for treating persistent high-risk human papillomavirus (HPV) infection; VTP-1000, an autoimmune preclinical candidate designed to treat patients with celiac disease; VTP-1100 product candidate to target HPV16+ cancers; and VTP-850/850, a second-generation immunotherapeutic candidate under phase 2 studies to treat recurrent prostate cancer. It is also involved in the development of partnered candidates, such as AB-729-202, which is under phase 2a studies for the treatment of patients with chronic HBV infection; VTP-600, an immunotherapy candidate under phase 1 studies as a potential treatment for NSCLC in combination with standard of care treatment, chemotherapy, and pembrolizumab; VTP-500, a prophylactic vaccine product candidate under phase 1 studies to prevent infection and subsequent disease caused by the MERS coronavirus; and VTP-400, a prophylactic vaccine candidate under phase 1 studies to prevent shingles in adults aged 50 years and older. In addition, the company offers Vaxzevria (formerly VTP-900 and AZD1222), a prophylactic vaccine for the prevention of COVID-19 Infection. Further, it has license, research and development, and collaboration agreements with OUI, NIH, IMC, CanSino, CRUK; VOLT; and Arbutus. The company was formerly known as Vaccitech plc and changed its name to Barinthus Biotherapeutics plc in November 2023. Barinthus Biotherapeutics plc was founded in 2016 and is headquartered in Didcot, the United Kingdom.Tharimmune NASDAQ:THAR$2.84 -0.10 (-3.40%) As of 07/2/2026Tharimmune, Inc., a clinical-stage biotechnology company, engages in the development of therapeutic candidates for rare, inflammatory, and oncologic diseases. The company's pre-clinical immuno-oncology pipeline includes TH104, a product candidate for the treatment of liver-related and other pruritogenic inflammatory conditions; TH3215 and TH0059 that are product candidates used to treat various solid tumors; and TH1940, which targets programmed cell death protein 1 (PD-1). It has a research collaboration and product license agreement with Minotaur Therapeutics, Inc. for the development of proprietary targeted biologics; and Washington University in St. Louis for the rights to develop and commercialize technology related to multiple hybridomas and antibodies directed specifically towards human HER2. The company was formerly known as Hillstream BioPharma, Inc. and changed its name to Tharimmune, Inc. in September 2023. Tharimmune, Inc. was incorporated in 2017 and is headquartered in Bridgewater, New Jersey. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 06/29 - 07/03 Why Flywire and Airbnb Could Be Quiet Winners of a Ceasefire Meta’s AI Compute Push Could Turn Its Massive CapEx Bill Into a Competitive Weapon Klarna’s Google Court Win Could Give Its BNPL Story a Needed Cash Catalyst SanDisk’s Volatility May Be Telling Bulls What They Want to Hear Broadcom and OpenAI Unveil Jalapeño: An Early Step to Massive AI Growth Potential Why the Comcast Spin-Off Won't Fix What's Actually Broken Shorting the Grid: Bloom Energy’s $25B AI Power Play Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
